
November 30, 2023
RegMed Investors’ (RMi) pre-open: What goes up, flops down and then switches directional roles
November 29, 2023
RegMed Investors (RMi) Research Financing Note: Verve Therapeutics (VERV) has priced its public offering of 12.5 M shares at $10.00
November 29, 2023
RegMed Investors (RMi) Closing Bell: good and bad news shakes the share pricing tree
November 28, 2023
RegMed Investors (RMi) Closing Bell: tug-of-war between red and green rope that closed gray
November 28, 2023
RegMed Investors’ (RMi) pre-open: A market hangover and a sector kerfuffle
November 27, 2023
RegMed Investors (RMi) Closing Bell: Cell and gene therapy sector slips
November 27, 2023
RegMed Investors’ (RMi) pre-open: trading ranges are perceiving resistance through the enthusiastic fog of the winning streak?
November 25, 2023
RegMed Investors (RMi) Closing Bell: bada, bing, bada-boom
November 24, 2023
RegMed Investors’ (RMi) pre-open: indexes in the bag or due for a snag?
November 21, 2023
RegMed Investors’ (RMi) pre-open: gobble, gobble
35 companies, 1 interpreter!
Insight, foresight and recommendation
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors